Table 4.
Questionnaire 1 | Pre-treatment examination | 3-month follow-up | 1-year follow-up† | 3-year follow-up‡ | |||
---|---|---|---|---|---|---|---|
n | Mean (s.d.) | Mean (s.d.) | Mean (s.d.) | Mean (s.d.) | Mean (s.d.) | P-value* | |
Treatment group | |||||||
Intra-oral index (PP) | 18 | 8·6 (6·9) | 6·6 (3·8) | 6·7 (4·5) | 4·7 (5·2) | 5·2 (3·8) | 0·026 |
Intra-oral index (ITT) | 20 | 8·4 (6·6) | 6·8 (3·7) | 6·4 (4·5) | 4·8 (5·0) | 4·9 (3·8) | 0·015 |
Extra-oral index (PP) | 18 | 6·7 (8·8) | 6·7 (7·1) | 5·7 (6·4) | 2·4 (3·2) | 4·8 (4·3) | 0·004§ |
Extra-oral index (ITT) | 20 | 6·9 (8·4) | 6·8 (6·8) | 5·6 (6·3) | 2·8 (3·8) | 4·9 (4·4) | 0·009§ |
General index (PP) | 18 | 41·4 (16·4) | 42·9 (21·3) | 39·0 (24·3) | 32·1 (19·2) | 31·6 (14·5) | 0·001 |
General index (ITT) | 20 | 41·5 (16·0) | 42·7 (20·4) | 37·9 (23·2) | 31·6 (18·5) | 31·4 (13·9) | <0·001 |
Reference group | |||||||
Intra-oral index (PP) | 12 | 11·0 (12·0) | n.a. | n.a. | 10·8 (12·8) | 15·4 (13·4) | 0·245§ |
Intra-oral index (ITT) | 20 | 13·0 (12·0) | n.a. | n.a. | 11·3 (12·4) | 13·6 (12·2) | 0·246§ |
Extra-oral index (PP) | 12 | 10·8 (10·6) | n.a. | n.a. | 9·4 (11·4) | 12·5 (12·6) | 0·179§ |
Extra-oral index (ITT) | 20 | 11·0 (9·3) | n.a. | n.a. | 10·0 (10·0) | 11·6 (10·8) | 0·259§ |
General index (PP) | 12 | 43·1 (18·1) | n.a. | n.a. | 38·3 (23·3) | 49·5 (28·5) | 0·004§ |
General index (ITT) | 20 | 47·3 (21·2) | n.a. | n.a. | 41·3 (25·2) | 49·6 (27·3) | 0·004§ |
n.a., not applicable.
P-value from analysis of variance for repeated measures.
For the reference group, mean index scores from Questionnaire 2 were used.
For the reference group, mean index scores from Questionnaire 3 were used.
Wilks’ Lambda.